Breaking News

Neurosterix Launches with $63M Series A Financing

Aims to advance allosteric modulator therapeutics for neurological disorders.

Author Image

By: Charlie Sternberg

Associate Editor

Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.   Neurosterix leverages decades of investment made by Addex in building a leading allosteric modulator discovery technology platform. The platform has a track record of identifyi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters